ImmTOR™ Technology
Overcoming immunogenicity to transform the lives of patients.
What is ImmTORTM?
Selecta Biosciences’ immune tolerance platform, ImmTORTM, is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses.
ImmTORTM has the potential to unlock the full potential of biologic therapies, including enabling redosing of life saving gene therapies, and to restore self-tolerance in autoimmune diseases.
The Science Behind ImmTORTM
Generating specific immune tolerance
Unwanted immunogenicity can compromise the efficacy and safety of a biologic drug.
Controlled, scalable manufacturing
The universal formulation of ImmTORTM is produced at a commercial scale via a well-controlled and scalable manufacturing process.
Selecta has developed a commercial-scale, Good Manufacturing Practice (GMP), process to ensure that ImmTOR is consistently produced and controlled according to quality standards.
ImmTOR’s tolerogenic activity has been reproduced in multiple independent laboratories using a range of biologic therapies and immunogenic antigens, validating the platform’s ability to mitigate anti-drug antibodies. This research has been published in several high-level peer-reviewed journals including Nature Nanotechnology, Nature Communications and Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Partnerships
Partner with us to unlock the potential of ImmTORTM
Our ImmTOR platform has exciting potential across a broad range of therapeutic areas. Learn more about our partnerships and partnering opportunities.

Building on the Success of SEL-212
Our ImmTORTM platform is clinically validated
With a Phase 3 clinical program in chronic refractory gout that has been strategically licensed to Sobi, Selecta’s ImmTOR platform is clinically validated to mitigate the immunogenicity of a fungal-derived enzyme. Selecta intends to build on this track record of success by combining ImmTOR with other biologics to create a pipeline of novel tolerogenic therapies.
AAV Vector Gene Therapies
Selecta is leveraging its ImmTOR platform to mitigate the body’s immune response to adeno-associated virus (AAV) vector gene therapies, potentially unlocking their full therapeutic potential.
Our Pipeline
Advancing novel tolerogenic therapies
With our clinically validated ImmTOR platform, we intend to build on our track record of success as we advance new tolerogenic therapies through development. Dig deep into our pipeline of ImmTOR-driven therapies.
